Boston Scientific Corporation
BSX
$101.55
$2.632.66%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.85B | 1.79B | 1.83B | 1.77B | 1.59B |
| Total Depreciation and Amortization | 1.27B | 1.23B | 1.23B | 1.22B | 1.20B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 774.00M | 752.00M | 761.00M | 479.00M | 484.00M |
| Change in Net Operating Assets | -462.00M | -843.00M | -1.19B | -990.00M | -770.00M |
| Cash from Operations | 3.44B | 2.94B | 2.63B | 2.48B | 2.50B |
| Capital Expenditure | -790.00M | -780.00M | -791.00M | -779.00M | -711.00M |
| Sale of Property, Plant, and Equipment | 3.00M | 1.00M | 2.00M | 2.00M | 4.00M |
| Cash Acquisitions | -4.64B | -2.02B | -888.00M | -1.48B | -1.81B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -260.00M | -242.00M | -129.00M | -115.00M | -56.00M |
| Cash from Investing | -5.69B | -3.04B | -1.81B | -2.38B | -2.57B |
| Total Debt Issued | 2.36B | 2.17B | 2.11B | 2.15B | 0.00 |
| Total Debt Repaid | -529.00M | -529.00M | -533.00M | -533.00M | -4.00M |
| Issuance of Common Stock | 230.00M | 219.00M | 198.00M | 199.00M | 182.00M |
| Repurchase of Common Stock | -87.00M | -56.00M | -56.00M | -56.00M | -56.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 0.00 | 0.00 | -14.00M | -28.00M |
| Other Financing Activities | -156.00M | -186.00M | -93.00M | -98.00M | -89.00M |
| Cash from Financing | 1.81B | 1.62B | 1.62B | 1.64B | 5.00M |
| Foreign Exchange rate Adjustments | -11.00M | 2.00M | -9.00M | -11.00M | -4.00M |
| Miscellaneous Cash Flow Adjustments | -1.00M | -- | 1.00M | 0.00 | 0.00 |
| Net Change in Cash | -450.00M | 1.52B | 2.44B | 1.73B | -70.00M |